Clinical trial results
for advanced gastroesophageal
cancer
For certain previously untreated adults with
advanced gastric cancer, gastroesophageal
junction cancer, and esophageal adenocarcinomas that tests positive for PD-L1
Actor portrayals.
An FDA-approved combination of immunotherapy and chemotherapy that helped people live longer compared to chemotherapy alone
About the clinical trial
In a clinical trial of 1581 patients with previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinomas who had quantifiable combined positive score (CPS) PD-L1 expression at baseline, 641 people were given OPDIVO + chemotherapy and 655 people were given chemotherapy alone. The chemotherapy used for both groups in this clinical trial was modified FOLFOX-6 (leucovorin, fluorouracil, and oxaliplatin) or CapeOX (capecitabine and oxaliplatin).
People given OPDIVO + chemotherapy lived longer compared to chemotherapy alone
OPDIVO + chemotherapy
Half the people were alive
Chemotherapy alone
Half the people were alive
In the primary analysis with a follow-up time of 1 year, people given OPDIVO + chemotherapy had a 23% lower risk of dying than those given chemotherapy alone.
More people given OPDIVO + chemotherapy saw their tumors shrink or disappear completely compared to chemotherapy alone at 1 year (primary analysis)
OPDIVO + chemotherapy |
Chemotherapy alone |
Tumors disappeared completely (complete response)
Tumors shrank (partial response)
Tumors shrank or disappeared completely (overall response)
Words to know
Combined positive score is a way of counting the number of PD-L1 positive cells.
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
OPDIVO + chemotherapy will not work for everyone. Individual results may vary.
“I can’t think of anything in this world that I would trade for my family.”
Kim’s story
Kim is a proud grandmother, mother, and wife who was diagnosed with advanced gastroesophageal junction cancer. With the support of her family and doctor, Kim decided that OPDIVO + chemotherapy was the right treatment choice for her.
“The first words out of my mouth were: ‘Let’s get a game plan.’”
Rob’s story
Rob is a husband, father of two, and former coach for kids' sports teams. See how he, his wife, and his doctor made a game plan with OPDIVO + chemotherapy for advanced esophageal cancer.
Should I ask my doctor about OPDIVO + chemotherapy?
Talk to your doctor about a potential first treatment option for advanced gastroesophageal cancer.
Getting an infusion
See your recommended treatment plan and what to expect from an infusion
For certain previously untreated adults with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinomas
OPDIVO® (nivolumab) is a prescription medicine used in combination with chemotherapy that contains fluoropyrimidine and platinum to treat adults with cancer of the stomach (gastric cancer), cancer where the esophagus joins the stomach (gastroesophageal junction cancer), and with esophageal adenocarcinoma when your cancer cannot be removed with surgery or has spread, and your tumors are positive for PD-L1.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.